Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Receives $32.50 Consensus Price Target from Analysts

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) has been assigned an average rating of “Moderate Buy” from the nine research firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and seven have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $32.50.

A number of research firms have recently commented on GLUE. Weiss Ratings upgraded shares of Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research note on Monday, May 11th. Wall Street Zen downgraded shares of Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Guggenheim cut their target price on shares of Monte Rosa Therapeutics from $34.00 to $30.00 and set a “buy” rating for the company in a research note on Wednesday, March 18th. JPMorgan Chase & Co. raised their target price on shares of Monte Rosa Therapeutics from $30.00 to $31.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Finally, Wells Fargo & Company cut their target price on shares of Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating for the company in a research note on Wednesday, March 18th.

Monte Rosa Therapeutics Price Performance

Monte Rosa Therapeutics stock opened at $17.76 on Wednesday. The firm has a 50-day moving average of $18.57 and a 200-day moving average of $18.45. Monte Rosa Therapeutics has a one year low of $4.12 and a one year high of $25.77. The company has a market cap of $1.50 billion, a price-to-earnings ratio of -12.00 and a beta of 1.60.

Monte Rosa Therapeutics (NASDAQ:GLUE) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). Monte Rosa Therapeutics had a negative return on equity of 40.99% and a negative net margin of 302.69%.The business had revenue of $4.21 million for the quarter, compared to analyst estimates of $10.95 million. As a group, sell-side analysts expect that Monte Rosa Therapeutics will post -1.23 earnings per share for the current year.

Insider Activity

In other Monte Rosa Therapeutics news, insider Philip Nickson sold 5,845 shares of the stock in a transaction dated Thursday, April 9th. The shares were sold at an average price of $17.69, for a total value of $103,398.05. Following the transaction, the insider directly owned 55,000 shares of the company’s stock, valued at $972,950. This represents a 9.61% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Jennifer Champoux sold 2,175 shares of the stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $20.00, for a total transaction of $43,500.00. Following the completion of the transaction, the chief operating officer directly owned 62,371 shares in the company, valued at approximately $1,247,420. This represents a 3.37% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 6.40% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Nisa Investment Advisors LLC increased its holdings in shares of Monte Rosa Therapeutics by 16.7% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,151 shares of the company’s stock worth $49,000 after purchasing an additional 451 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in Monte Rosa Therapeutics by 32.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,164 shares of the company’s stock valued at $50,000 after acquiring an additional 776 shares during the last quarter. Royce & Associates LP increased its stake in Monte Rosa Therapeutics by 8.3% in the third quarter. Royce & Associates LP now owns 11,024 shares of the company’s stock valued at $82,000 after acquiring an additional 848 shares during the last quarter. ProShare Advisors LLC increased its stake in Monte Rosa Therapeutics by 11.8% in the fourth quarter. ProShare Advisors LLC now owns 11,374 shares of the company’s stock valued at $178,000 after acquiring an additional 1,199 shares during the last quarter. Finally, MetLife Investment Management LLC increased its stake in Monte Rosa Therapeutics by 7.5% in the fourth quarter. MetLife Investment Management LLC now owns 26,187 shares of the company’s stock valued at $411,000 after acquiring an additional 1,831 shares during the last quarter. 79.96% of the stock is owned by institutional investors.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.